{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:19:07Z","timestamp":1769444347613,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"DOI":"10.7759\/cureus.102136","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:36:08Z","timestamp":1769168168000},"source":"Crossref","is-referenced-by-count":0,"title":["Letermovir Prophylaxis for Cytomegalovirus Infection in Adult Allogeneic Stem Cell Transplantation: A Retrospective Analysis From a Lower-Middle-Income Country"],"prefix":"10.7759","author":[{"given":"Neha","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Bhayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil M","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusha","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyash","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyeaghala","family":"Chizaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrinidhi","family":"Nathany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anindita","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02124-y","article-title":"CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation","volume":"59","author":"Malagola M","year":"2024","unstructured":"Malagola M, Radici V, Farina M, et al.. CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2024, 59:138-40. 10.1038\/s41409-023-02124-y","journal-title":"Bone Marrow Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.7.8","article-title":"Letermovir for cytomegalovirus prevention in patients undergoing hematopoietic cell transplantation","volume":"10","author":"Daniels K","year":"2019","unstructured":"Daniels K, Clemmons A. Letermovir for cytomegalovirus prevention in patients undergoing hematopoietic cell transplantation. J Adv Pract Oncol. 2019, 10:730-5. 10.6004\/jadpro.2019.10.7.8","journal-title":"J Adv Pract Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty FM","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, et al.. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017, 377:2433-44. 10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira P","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, et al.. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016, 127:2427-38. 10.1182\/blood-2015-11-679639","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"7","author":"Ljungman P","year":"2017","unstructured":"Ljungman P, de la Camara R, Robin C, et al.. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet. 2017, 7:260-72. 10.1016\/S1473-3099(19)30107-0","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00081-7","article-title":"CMV infections after HSCT: prophylaxis and treatment","volume":"60","author":"Chung H","year":"2025","unstructured":"Chung H. CMV infections after HSCT: prophylaxis and treatment. Blood Res. 2025, 60:33. 10.1007\/s44313-025-00081-7","journal-title":"Blood Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pit048","article-title":"Ganciclovir, foscarnet, and cidofovir: antiviral drugs not just for cytomegalovirus","volume":"2","author":"Upadhyayula S","year":"2013","unstructured":"Upadhyayula S, Michaels MG. Ganciclovir, foscarnet, and cidofovir: antiviral drugs not just for cytomegalovirus. J Pediatric Infect Dis Soc. 2013, 2:286-90. 10.1093\/jpids\/pit048","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 Trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty FM","year":"2019","unstructured":"Marty FM, Winston DJ, Chemaly RF, et al.. A randomized, double-blind, placebo-controlled phase 3 Trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019, 25:369-81. 10.1016\/j.bbmt.2018.09.038","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens J","year":"2019","unstructured":"Maertens J, Cordonnier C, Jaksch P, et al.. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019, 381:1136-47. 10.1056\/NEJMoa1714656","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S79131","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez DP","year":"2015","unstructured":"Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist. 2015, 8:269-77. 10.2147\/IDR.S79131","journal-title":"Infect Drug Resist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83035","article-title":"Bioequivalent letermovir usage for prophylaxis in haploidentical stem cell transplantation at high risk of CMV reactivation: a report of two cases from India","volume":"17","author":"Nag A","year":"2025","unstructured":"Nag A, Kt B, Kumar J, et al.. Bioequivalent letermovir usage for prophylaxis in haploidentical stem cell transplantation at high risk of CMV reactivation: a report of two cases from India. Cureus. 2025, 17:e83035. 10.7759\/cureus.83035","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman P","year":"2020","unstructured":"Ljungman P, Schmitt M, Marty FM, et al.. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020, 70:1525-33. 10.1093\/cid\/ciz490","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2024.2024.0026","article-title":"Real-Life Data on the efficacy and safety of letermovir for primary prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients: a single-center analysis","volume":"41","author":"W\u0142odarczyk M","year":"2024","unstructured":"W\u0142odarczyk M, Wieczorkiewicz-Kabut A, Bia\u0142as K, Kocl\u0119ga A, Noster I, Zieli\u0144ska P, Helbig G. Real-Life Data on the efficacy and safety of letermovir for primary prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients: a single-center analysis. Turk J Haematol. 2024, 41:9-15. 10.4274\/tjh.galenos.2024.2024.0026","journal-title":"Turk J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu LW","year":"2022","unstructured":"Liu LW, Yn A, Gao F, et al.. Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transplant Cell Ther. 2022, 28:510.e1-9. 10.1016\/j.jtct.2022.05.020","journal-title":"Transplant Cell Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010966","article-title":"Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant","volume":"7","author":"Lin A","year":"2023","unstructured":"Lin A, Brown S, Chinapen S, et al.. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant. Blood Adv. 2023, 7:7153-60. 10.1182\/bloodadvances.2023010966","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2024.101565","article-title":"Cytomegalovirus in haematopoietic cell transplantation - the troll is still there","volume":"37","author":"Voigt S","year":"2024","unstructured":"Voigt S. Cytomegalovirus in haematopoietic cell transplantation - the troll is still there. Best Pract Res Clin Haematol. 2024, 37:101565. 10.1016\/j.beha.2024.101565","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456385-letermovir-prophylaxis-for-cytomegalovirus-infection-in-adult-allogeneic-stem-cell-transplantation-a-retrospective-analysis-from-a-lower-middle-income-country","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:36:10Z","timestamp":1769168170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456385-letermovir-prophylaxis-for-cytomegalovirus-infection-in-adult-allogeneic-stem-cell-transplantation-a-retrospective-analysis-from-a-lower-middle-income-country"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.102136","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}